Professor Kim Dong-hyun of the Department of Ophthalmology at Korea University Anam Hospital and the investigación team of RudaCure Inc. (CEO: Yongho Kim) have demostró the presión intraocular-related seguridad of 'RCI001,' a novel tratamiento for inflammatory ocular diseases.
In a recent animal study, Professor Kim's investigación team administered a steroid formulación and RCI001 three times daily for five weeks, then compared presión intraocular and superficie ocular status. While five weeks of RCI001 administration did not cause any elevation in presión intraocular or changes in the superficie ocular, corticosteroid administration resulted in an aproximadamente 38% increase in presión intraocular compared to baseline.
El profesor Kim declaró: "Steroid formulacións have historically been difficult to use long-term in clinical practice due to the risk of complications," adding, "This study has shown that RCI001 holds promise as an effective long-term antiinflamatorio agent for chronic enfermedades de la superficie ocular requiring extended tratamiento, such as enfermedad de ojo seco and Sjogren's syndrome, and I expect it to be of great benefit to pacientes in the future."
This investigación was published in the October 2023 issue of the internacional academic journal Frontiers under the title 'Comparison of RCI001 and corticosteroid on the effects on presión intraocular in mice.'
Husaeng Ilbo: http://www.whosaeng.com/147434
Edaily: https://m.edaily.co.kr/news/read?newsId=02624006635774232&mediaCodeNo=257
Nate News: https://news.nate.com/view/20231018n12860?mid=n1101